Evolving Market Trends In The MSI-H And dMMR Industry: Innovative Combination Therapies Transforming MSI-H And dMMR Cancer Treatment

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Expected MSI-H And dMMR Market Size During the Forecast Period?
The market size for MSI-H and dMMR has witnessed an exponential increase in the past few years. The market which is expected to be worth $6.15 billion in 2024 is projected to escalate to $7.59 billion in 2025, displaying a compound annual growth rate (CAGR) of 23.3%. The significant growth in the historical duration can be credited to the surging cases of colorectal and endometrial cancers, broader genetic screening programs, the increasing use of MSI testing in clinics, heightened awareness about hereditary cancer syndromes, and an uptick in the use of liquid biopsies.

In the upcoming years, it's anticipated that the market size of MSI-H and dMMR will witness an enormous growth, reaching $17.40 billion in 2029 with a CAGR of 23.1%. This expected growth during the forecasted period is attributed to factors such as the escalating demand for customized cancer treatments, the widening use of next-generation sequencing, growing investments in oncology healthcare, the increasing number of clinical trials involving immune checkpoint inhibitors, and favorable regulatory backing for companion diagnostics. Key market trends predicted in the forecast period comprise of the incorporation of artificial intelligence into diagnostic procedures, alliances forming between pharmaceutical and diagnostic firms, the creation of multiplex biomarker panels, innovations in immunotherapy, and a shift toward pan-cancer biomarker examination.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

What Are the High-Growth Segments in the MSI-H And dMMR Market?
The MSI-H and dMMR market covered in this report is segmented -

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy
2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications
3) By Stage: Early Stages, Advanced Stages
4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:
1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What Key Drivers Are Expected to Influence Future MSI-H And dMMR Market Growth?
The increasing incidence of cancer is predicted to drive the expansion of the MSI-H and dMMR market. Cancer is a collection of illnesses distinguished by the unregulated proliferation and dissemination of abnormal cells within the body. The escalating incidence of cancer is chiefly due to the aging population, as the odds of getting cancer significantly amplifies with age due to the aggregate impact of genetic mutations and extended exposure to risk elements over time. MSI-H and dMMR play a pivotal role in detecting cancer tumors that have high mutation proportions owing to defects in DNA repair mechanisms. These biomarkers are instrumental in steering decisions regarding immunotherapy since such tumors have a higher probability of reacting to immune checkpoint inhibitors. They also provide a profound understanding of prognosis and potential genetic syndromes. For example, in January 2024, the American Cancer Society, a non-profit organization based in the US, claimed that in 2023 about 1,958,310 new cancer instances and 609,820 cancer-linked deaths were expected to occur in the United States. These figures are anticipated to soar in 2024, with nearly 2,001,140 new cases of cancer and 611,720 deaths expected, underlining a constant surge in cancer prevalence and mortality. Consequently, the escalating incidence of cancer is fuelling the growth of the MSI-H and dMMR market.

Which Companies Hold the Largest Share Across Different MSI-H And dMMR Market Segments?
Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

What MSI-H And dMMR Market Trends Are Gaining Traction Across Different Segments?
Key players in the MSI-H and dMMR market are concentrating their efforts on developing cutting-edge therapies such as combination therapy with the aim of increasing the effectiveness of treatments and enhancing the outcomes for patients. Combination therapy for MSI-H and dMMR cancers utilizes several treatment methods simultaneously, often involving immunotherapy agents like checkpoint inhibitors or a combination of immunotherapy with chemotherapy, targeted therapy, or radiation. The objective is to intensify the response to treatment, surmount resistance, and boost the survival rates of patients who have tumors exhibiting high microsatellite instability or deficient mismatch repair. Case in point, in April 2025, the US-based pharmaceutical firm, Bristol-Myers Squibb Company, was granted approval by the United States Food and Drug Administration (FDA) for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as an initial treatment option for metastatic colorectal cancer (mCRC) featuring microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), which propels treatment alternatives for this complex cancer subtype. This clearance signifies a noteworthy breakthrough in the treatment of MSI-H and dMMR cancers, as it introduces a novel, impactful therapeutic choice that acts on multiple routes to extend patient survival and increase response rates, effectively addressing the unfulfilled medical needs of these patients.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

What Are the Emerging Geographies for The MSI-H And dMMR Market Growth?
North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the MSI-H And dMMR Market?
2. What is the CAGR expected in the MSI-H And dMMR Market?
3. What Are the Key Innovations Transforming the MSI-H And dMMR Industry?
4. Which Region Is Leading the MSI-H And dMMR Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.